Soluble proteoglycans and proteoglycan fragments as biomarkers of pathological extracellular matrix remodeling
Author(s)
Kemberi, Marsioleda
Minns, Alexander F
Santamaria, Salvatore
Type
Journal Article
Abstract
Proteoglycans and their proteolytic fragments diffuse into biological fluids such as plasma, serum, urine, or synovial fluid, where they can be detected by antibodies or mass-spectrometry. Neopeptides generated by the proteolysis of proteoglycans are recognized by specific neoepitope antibodies and can act as a proxy for the activity of certain proteases. Proteoglycan and proteoglycan fragments can be potentially used as prognostic, diagnostic, or theragnostic biomarkers for several diseases characterized by dysregulated extracellular matrix remodeling such as osteoarthritis, rheumatoid arthritis, atherosclerosis, thoracic aortic aneurysms, central nervous system disorders, viral infections, and cancer. Here, we review the main mechanisms accounting for the presence of soluble proteoglycans and their fragments in biological fluids, their potential application as diagnostic, prognostic, or theragnostic biomarkers, and highlight challenges and opportunities ahead of their clinical translation.
Date Issued
2024-10-01
Date Acceptance
2024-10-23
Citation
Proteoglycan Research, 2024, 2 (4)
ISSN
2832-3556
Publisher
Wiley
Journal / Book Title
Proteoglycan Research
Volume
2
Issue
4
Copyright Statement
© 2024 The Author(s). Proteoglycan Research published by Wiley Periodicals LLC. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
License URL
Identifier
https://www.ncbi.nlm.nih.gov/pubmed/39600538
PII: PGR270011
Subjects
ADAMTS
aggrecan
matrix metalloproteinases
neoepitope antibodies
proteases
proteoglycans
shedding
syndecans
versican
Publication Status
Published
Coverage Spatial
United States
Article Number
e70011
Date Publish Online
2024-11-16